FINWIRES · TerminalLIVE
FINWIRES

Yamabiko to Liquidate Dubai Subsidiary Amid Middle East Instability

By

Yamabiko (TYO:6250) said it will dissolve and liquidate its wholly owned UAE subsidiary, Yamabiko General Trading, citing worsening instability in the Middle East, according to a Thursday filing on the Tokyo Stock Exchange.

The company said it established the Dubai-based subsidiary in December 2025 to expand operations in the Middle East, but determined it would be difficult to achieve the stable business environment initially envisioned, even if regional tensions ease.

Yamabiko said it decided to prioritize risk avoidance and management resource optimization.

The company said its headquarters will directly oversee operations in the region going forward while maintaining product supply and support for distributors in Turkey and other Middle Eastern markets.

Related Articles

Asia

Hansoh Pharma Gets China Nod for Trial of Tumor Drug

Hansoh Pharmaceutical's (HKG:3692) obtained clinical trial approval for its HS-10541 tablets from China's National Medical Products Administration, according to a Wednesday Hong Kong bourse filing.Shares of the pharma firm were down over 1% in Thursday afternoon trading.The trial will study the drug for the treatment of patients with KRAS G12C-mutated advanced solid tumors.

$HKG:3692
Asia

Kehua Bio-Engineering's Unit Gets Registration Certificate for Metapneumovirus Nucleic Acid Kit

Shanghai Kehua Bio-Engineering's (SHE:002022) unit, Suzhou Tianlong Biotechnology, received a medical device registration certificate from China's National Medical Products Administration for a swab kit for metapneumovirus nucleic acid, according to a Shenzhen bourse filing on Thursday.The certificate for the human metapneumovirus nucleic acid detection kit is valid until May 10, 2031.The Chinese in vitro diagnostics company's shares fell 2% during the afternoon trade.

$SHE:002022
Asia

CTBC Financial Books NT$5.4 Billion Profit in April

CTBC Financial (TPE:2891) booked a consolidated net profit of NT$5.40 billion for April, with pre-tax income of NT$6.58 billion, or according to a Thursday Taiwan Exchange filing.For the first four months of 2026, the group recorded an attribuatble net profit of NT$28.5 billion, or NT$1.46 per share.Meanwhile, cumulativewhile pre-tax income came in at NT$34.9 billion, the filing said.

$TPE:2891